Alk-Abello ASCHIX:ALKBC 92 Return-on-Tangible-Equity is 36.95% as of Mar. 2026, which is 290% above its 10-year median of 9.47. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr207.27 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Alk-Abello AS ranks better than 92.91% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Alk-Abello AS's annualized net income for the quarter that ended in Mar. 2026 was kr1,748 Mil. Alk-Abello AS's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr4,731 Mil. Therefore, Alk-Abello AS's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 36.95%.
The historical rank and industry rank for Alk-Abello AS's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:ALKBc'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -6.81 Med: 9.47 Max: 29.36
Current: 29.36
During the past 13 years, Alk-Abello AS's highest Return-on-Tangible-Equity was 29.36%. The lowest was -6.81%. And the median was 9.47%.
CHIX:ALKBc's Return-on-Tangible-Equity is ranked better than 92.91% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs CHIX:ALKBc: 29.36
Alk-Abello AS (CHIX:ALKBc) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Alk-Abello AS Return-on-Tangible-Equity Related Terms
Alk-Abello AS Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Alk-Abello AS's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 36.95% mean?
Alk-Abello AS (CHIX:ALKBC) has a Return-on-Tangible-Equity of 36.95% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alk-Abello AS and its competitors. This is 290% above median its historical median of 9.47. According to the industry distribution chart, Alk-Abello AS ranks #85 out of 1199 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Alk-Abello AS's Return-on-Tangible-Equity too high?
Alk-Abello AS's current Return-on-Tangible-Equity of 36.95% is 290% above median its 10-year median of 9.47. Based on the distribution chart, Alk-Abello AS ranks #85 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #85 out of 1199 companies for Return-on-Tangible-Equity. This places Alk-Abello AS in the top 7% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Alk-Abello AS and its competitors. Alk-Abello AS's current Return-on-Tangible-Equity is 36.95%, which is 290% above median its own 10-year median of 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr207.27, compared to a current price of kr256.30 — trading 23.7% above its estimated fair value. The current Return-on-Tangible-Equity is 36.95%, which is 290% above median its 10-year median of 9.47. Alk-Abello AS's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Return-on-Tangible-Equity is 36.95% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.7% above its estimated GF Value™ of kr207.27.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
Return-on-Tangible-Equity: 36.95% (290% above median its 10-year median of 9.47)
GF Value™: kr207.27 vs. price of kr256.30 (23.7% above fair value)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
